ClinicalTrials.gov
public full text
Public Domain
Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors
RATIONALE: Biological therapy uses different ways to stimulate the immune system and stop cancer cells from growing. Cytotoxic T cells combined with interleukin-2 may be an effective treatment for recurrent brain tumors. PURPOSE: Phase I trial to study the effectiveness of cytotoxic T cells and interleukin-2 in treating adults with recurrent brain tumors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas#1126761
- Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors#1194812
- The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM#1415211
- ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse#856553
- Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma#801583
Record · ID 1462912
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive